Abstract: The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in procaryotic cells are provided. Recombinant PAV viruses are obtained by transfection of mammalian cells with recombinant PAV genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals. In addition, PAV-3 vectors can be used for gene therapy and expression of heterologous polypeptides. PAV-3 genome sequences can also be used for diagnostic purposes, to detect the presence of PAV-3 DNA in a subject or biological sample.

Abstract: The present invention relates to methods for culturing circovirus and in particular, porcine circovirus. The present invention provides compositions and methods for culturing porcine circovirus in mammalian cells expressing mammalian adenovirus E1 function.

Abstract: The invention provides cell lines capable of supporting the replication of a defective recombinant virus vector. In one aspect, bovine cell lines expressing adenovirus E1 functions are provided. The cell lines are useful for the propagation of adenovirus vectors with mutations and/or deletions in E1 and other essential regions of the adenovirus genome.

Abstract: Methods of nucleic acid immunization comprising the in utero delivery of nucleic acid molecules that encode one or more selected antigens to a vertebrate fetus are disclosed.

Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.

Abstract: The present invention provides novel recombinant mammalian cell lines expressing bovine adenovirus functions. In one embodiment, mammalian cell lines stably transformed with bovine adenovirus E1 sequences express bovine adenovirus E1 gene products and are useful for the replication of bovine adenovirus vectors having deletions and/or insertions in the E1 region. Such vector/cell line combinations are useful for synthesis of recombinant polypeptides, preparation of subunit vaccines, and in gene therapy.

Abstract: The present invention provides modified bovine adenoviruses comprising a modification in a capsid protein wherein said protein is associated with adenovirus tropism and wherein said modification is associated with altered tropism. The present invention provides adenovirus vectors and host cells comprising such vectors. The present invention also provides methods of making and using such adenoviruses.

Abstract: The present invention provides the complete nucleotide sequence of a bovine adenovirus. The invention further provides bovine adenovirus vectors and expression systems which can be used, among other things, for insertion of foreign sequences, for provision of DNA control sequences including transcriptional and translational regulatory sequences, for diagnostic purposes to detect the presence of viral nucleic acids or proteins encoded by these regions in a subject or biological sample, for provision of immunogenic polypeptides or fragments thereof, for vaccines and for gene therapy. Cell lines comprising the vectors of the invention, and methods for making bovine adenovirus vectors are also provided.

Abstract: Vaccines compositions comprising a pharmaceutically acceptable vehicle and a mutant bovine herpesvirus 1 (BHV-1) wherein (i) at least one non-essential gene of wild-type BHV-1 is deleted and optionally replaced with a gene selected from the group consisting of a foreign gene, a gene encoding a BHV-1 immunogen and a mutant analog of a gene encoding a BHV-1 immunogen; and wherein (ii) the replacement gene is optionally under the control of a promoter; and further wherein (iii) at least one essential gene of wild-type BHV-1 is optionally mutated are provided. Vaccines compositions comprising a pharmaceutically acceptable vehicle and a bovine herpesvirus 1 (BHV-1) wherein at (i) least one non-essential gene is deleted or (ii) an essential gene is mutated are also provided. In addition, related vectors, DNA constructs, a diagnostic assay and methods for treating and preventing BHV-1 infection and other bacterial and viral pathogens of cattle are provided.

Abstract: The present invention relates novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.

Abstract: The present invention provides recombinant bovine adenovirus (BAV) vectors and expression systems for introduction and expression of non-BAV sequences in mammalian cells. Methods for the preparation and use of these vectors and expression systems are also provided.

Abstract: Recombinant subunit vaccines against bovine herpesvirus type 1 (BHV-1) are provided, as well as methods of vaccination and methods of recombinantly producing the subunit antigens or nucleotide sequences employed in the vaccines.

Abstract: Recombinant subunit vaccines against bovine herpesvirus type 1 (BHV-1) are provided, as well as methods of vaccination and methods of recombinantly producing the subunit antigens or nucleotide sequences employed in the vaccines.

Abstract: The present invention relates novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.

Abstract: Nucleic acid sequences encoding the Bovine Coronavirus E2 (or BCV S) and E3 (or BCV HE) structural glycoproteins and methods of producing these proteins, including recombinant expression, e.g., in mammalian or insect cells, are provided. The E2 and E3 proteins or antigenic fragments thereof are useful components for Bovine Coronavirus vaccines and methods of treatment.

Abstract: Recombinant subunit vaccines against bovine herpesvirus type 1 (BHV-1) are provided, as well as methods of vaccination, methods of recombinantly producing the subunit antigens or nucleotide sequences encoding the BHV-1 gI, gIII and gIV proteins employed in the vaccines.

Abstract: Bovine coronavirus (BCV) E2 and E3 coding sequences and materials for producing the proteins E2 and E3 are provided. E2, E3, or antigenic fragments thereof are useful components for a BCV vaccine.

Abstract: A method for treating or preventing mastitis in cows is disclosed. The method contemplates the intramammary injection of bovine interferon-gamma. Interferon-gamma can be administered prior to infection to effectively suppress the rate, severity, and duration of subsequent bacterial infection, or can be administered subsequent to infection to effectively treat mastitis.

Abstract: Subunit vaccines against bovine herpesvirus type 1 are provided, as well as methods of vaccination and methods of making the subunit antigen employed in the vaccines.

Abstract: A method for treating or preventing mastitis in cows is disclosed. The method contemplates the intramammary injection of bovine interferon-gamma. Interferon-gamma can be administered prior to infection to effectively suppress the rate, severity, and duration of subsequent bacterial infection, or can be administered subsequent to infection to effectively treat mastitis.